{{PBB|geneid=1471}}
'''Cystatin C''' or '''cystatin 3''' (formerly '''gamma trace''', post-gamma-globulin or neuroendocrine basic polypeptide),<ref name="Alzforum">{{cite web |url=http://www.alzforum.org/res/com/gen/alzgene/geneoverview.asp?geneid=66 |title=Alzforum: AlzGene |format= |work= |accessdate=}}</ref> a [[protein]] encoded by the '''CST3''' [[gene]], is mainly used as a [[biomarker]] of [[kidney function]]. Recently, it has been studied for its role in predicting new-onset or deteriorating [[cardiovascular disease]]. It also seems to play a role in brain disorders involving [[amyloid]] (a specific type of protein deposition), such as [[Alzheimer's disease]]. 
In humans, all [[Cell (biology)|cells]] with a [[Cell nucleus|nucleus]] (cell core containing the [[DNA]]) produce cystatin C as a [[polypeptide|chain]] of 120 [[amino acid]]s. It is found in virtually all tissues and body fluids. It is a potent [[enzyme inhibitor|inhibitor]] of [[lysosome|lysosomal]] [[proteinase]]s ([[enzyme]]s from a special [[organelle|subunit of the cell]] that break down proteins) and probably one of the most important [[extracellular]] inhibitors of [[cysteine protease]]s (it prevents the breakdown of proteins outside the cell by a specific type of protein degrading enzymes). Cystatin C belongs to the type 2 [[cystatin]] [[gene family]].

==Role in medicine==
===Kidney function===
[[Renal function|Glomerular filtration rate]] (GFR), a marker of kidney health, is best measured by injecting compounds such as [[inulin]], [[radioisotope]]s such as <sup>51</sup>chromium-[[EDTA]], <sup>125</sup>I-iothalamate, <sup>99m</sup>Tc-[[DTPA]] or [[radiocontrast agent]]s such as [[iohexol]], but these techniques are complicated, costly, time-consuming and have potential side-effects.<ref name="pmid17361076">{{cite journal |author=Zahran A, El-Husseini A, Shoker A |title=Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review |journal=Am. J. Nephrol. |volume=27 |issue=2 |pages=197–205 |year=2007 |pmid=17361076 |doi=10.1159/000100907 |url=http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000100907}}</ref><ref name="pmid17316593"/>
Creatinine is the most widely used [[biomarker]] of kidney function. It is inaccurate at detecting mild renal impairment, and levels can vary with muscle mass and protein intake.<ref name="pmid8329667">{{cite journal |author=King AJ, Levey AS |title=Dietary protein and renal function |journal=J. Am. Soc. Nephrol. |volume=3 |issue=11 |pages=1723–37 |year=1993 |month=May |pmid=8329667 |doi= |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=8329667}}</ref>
Formulas such as the Cockcroft and Gault formula and the MDRD formula (see [[Renal function]]) try to adjust for these variables.

Cystatin C has a low [[molecular weight]] (approximately 13.3 [[kilodalton]]s), and it is removed from the bloodstream by [[glomerular filtration]] in the kidneys. If kidney function and glomerular filtration rate decline, the blood levels of cystatin C rise. Serum levels of cystatin C are a more precise test of kidney function (as represented by the [[glomerular filtration rate]], GFR) than serum [[creatinine]] levels.<ref name="pmid17316593">{{cite journal |author=Roos JF, Doust J, Tett SE, Kirkpatrick CM |title=Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children--a meta-analysis |journal=Clin. Biochem. |volume=40 |issue=5–6 |pages=383–391 |year=2007 |month=March |pmid=17316593 |doi=10.1016/j.clinbiochem.2006.10.026 |url=http://linkinghub.elsevier.com/retrieve/pii/S0009-9120(07)00005-7}}</ref><ref name="pmid12148093">{{cite journal |author=Dharnidharka VR, Kwon C, Stevens G |title=Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis |journal=Am. J. Kidney Dis. |volume=40 |issue=2 |pages=221–226 |year=2002 |month=August |pmid=12148093 |doi= 10.1053/ajkd.2002.34487|url=http://linkinghub.elsevier.com/retrieve/pii/S0272638602000343}}</ref> This finding is based mainly on [[Cross-sectional study|cross-sectional studies]] (on a single point in time). [[Longitudinal study|Longitudinal studies]] (that follow cystatin C over time) are scarcer; some studies show promising results.<ref name="pmid18319326">{{cite journal |author=Premaratne E, MacIsaac RJ, Finch S, Panagiotopoulos S, Ekinci E, Jerums G |title=Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes |journal=Diabetes Care |volume=31 |issue=5 |pages=971–973 |year=2008 |month=May |pmid=18319326 |doi=10.2337/dc07-1588 |url=http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=18319326}}</ref><ref name="pmid15788478">{{cite journal |author=Perkins BA |title=Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study |journal=J. Am. Soc. Nephrol. |volume=16 |issue=5 |pages=1404–1412 |year=2005 |month=May |pmid=15788478 |doi=10.1681/ASN.2004100854 |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=15788478 |pmc=2429917 |author-separator=, |author2=Nelson RG |author3=Ostrander BE |display-authors=3 |last4=Blouch |first4=KL |last5=Krolewski |first5=AS |last6=Myers |first6=BD |last7=Warram |first7=JH}}</ref><ref name="pmid16406933">{{cite journal |author=Corrao AM |title=Serum cystatin C as a reliable marker of changes in glomerular filtration rate in children with urinary tract malformations |journal=J. Urol. |volume=175 |issue=1 |pages=303–309 |year=2006 |month=January |pmid=16406933 |doi=10.1016/S0022-5347(05)00015-7 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(05)00015-7 |author-separator=, |author2=Lisi G |author3=Di Pasqua G |display-authors=3 |last4=Guizzardi |first4=M. |last5=Marino |first5=N. |last6=Ballone |first6=E. |last7=Lelli Chiesa |first7=P.}}</ref>
Cystatin C levels are less dependent on age, sex, race and muscle mass compared to creatinine. Cystatin C measurements alone have not been shown to be superior to formula-adjusted estimations of kidney function.<ref name="Stevens2008">{{cite journal |author=Stevens LA |title=Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD |journal=Am. J. Kidney Dis. |volume=51 |issue=3 |pages=395–406 |year=2008 |month=March |pmid=18295055 |doi=10.1053/j.ajkd.2007.11.018 |url=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(07)01594-6 |pmc=2390827 |author-separator=, |author2=Coresh J |author3=Schmid CH |display-authors=3 |last4=Feldman |first4=Harold I. |last5=Froissart |first5=Marc |last6=Kusek |first6=John |last7=Rossert |first7=Jerome |last8=Van Lente |first8=Frederick |last9=Bruce |first9=Robert D.}}</ref> As opposed to previous claims, cystatin C has been found to be influenced by body composition.<ref name="pmid17290239">{{cite journal |author=Shlipak MG |title=Cystatin C as a marker of glomerular filtration rate in chronic kidney disease: influence of body composition |journal=Nat Clin Pract Nephrol |volume=3 |issue=4 |pages=188–189 |year=2007 |month=April |pmid=17290239 |doi=10.1038/ncpneph0404}}</ref><ref name="pmid17059990">{{cite journal |author=Macdonald J |title=GFR estimation using cystatin C is not independent of body composition |journal=Am. J. Kidney Dis. |volume=48 |issue=5 |pages=712–719 |year=2006 |month=November |pmid=17059990 |doi=10.1053/j.ajkd.2006.07.001 |url=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(06)01159-0 |author-separator=, |author2=Marcora S |author3=Jibani M |display-authors=3 |last4=Roberts |first4=Gareth |last5=Kumwenda |first5=Mick |last6=Glover |first6=Ruth |last7=Barron |first7=Jeffrey |last8=Lemmey |first8=Andrew}}</ref>
It has been suggested that cystatin C might predict the risk of developing [[chronic kidney disease]], thereby signaling a state of 'preclinical' kidney dysfunction.<ref name="pmid16908914">{{cite journal |author=Shlipak MG |title=Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease |journal=Ann. Intern. Med. |volume=145 |issue=4 |pages=237–46 |year=2006 |month=August |pmid=16908914 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=reprint&pmid=16908914 |author-separator=, |author2=Katz R |author3=Sarnak MJ |display-authors=3 |last4=Fried |first4=LF |last5=Newman |first5=AB |last6=Stehman-Breen |first6=C |last7=Seliger |first7=SL |last8=Kestenbaum |first8=B |last9=Psaty |first9=B}}</ref>

Studies have also investigated cystatin C as a marker of kidney function in the adjustment of medication dosages.<ref name="pmid16778715">{{cite journal |author=Hermida J, Tutor JC |title=Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin |journal=Ther Drug Monit |volume=28 |issue=3 |pages=326–331 |year=2006 |month=June |pmid=16778715 |doi=10.1097/01.ftd.0000211805.89440.3d |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00007691-200606000-00010}}</ref><ref name="pmid15180169">{{cite journal |author=Schück O, Teplan V, Sibová J, Stollová M |title=Predicting the glomerular filtration rate from serum creatinine, serum cystatin C and the Cockcroft and Gault formula with regard to drug dosage adjustment |journal=Int J Clin Pharmacol Ther |volume=42 |issue=2 |pages=93–7 |year=2004 |month=February |pmid=15180169 |doi= |url=}}</ref>

Cystatin C levels have been reported to be altered in patients with cancer,<ref name="pmid16337174">{{cite journal |author=Demirtaş S, Akan O, Can M, Elmali E, Akan H |title=Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia |journal=Clin. Biochem. |volume=39 |issue=2 |pages=115–118 |year=2006 |month=February |pmid=16337174 |doi=10.1016/j.clinbiochem.2005.10.009 |url=http://linkinghub.elsevier.com/retrieve/pii/S0009-9120(05)00294-8}}</ref><ref name="pmid18317874">{{cite journal |author=Nakai K |title=Serum levels of cystatin C in patients with malignancy |journal=Clin. Exp. Nephrol. |volume=12 |issue=2 |pages=132–139 |year=2008 |month=April |pmid=18317874 |doi=10.1007/s10157-008-0043-8 |author-separator=, |author2=Kikuchi M |author3=Fujimoto K |display-authors=3 |last4=Kaneko |first4=Yoshito |last5=Omori |first5=So |last6=Nakai |first6=Kenji |last7=Suwabe |first7=Akira}}</ref><ref name="pmid9836733">{{cite journal |author=Kos J, Stabuc B, Cimerman N, Brünner N |title=Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression |journal=Clin. Chem. |volume=44 |issue=12 |pages=2556–7 |year=1998 |month=December |pmid=9836733 |doi= |url=http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=9836733}}</ref> (even subtle) thyroid dysfunction<ref name="pmid12675875">{{cite journal |author=Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C |title=Impact of thyroid dysfunction on serum cystatin C |journal=Kidney Int. |volume=63 |issue=5 |pages=1944–1947 |year=2003 |month=May |pmid=12675875 |doi=10.1046/j.1523-1755.2003.00925.x}}</ref><ref name="pmid15966508">{{cite journal |author=Manetti L |title=Thyroid function differently affects serum cystatin C and creatinine concentrations |journal=J. Endocrinol. Invest. |volume=28 |issue=4 |pages=346–9 |year=2005 |month=April |pmid=15966508 |doi= |url=http://www.kurtis.it/abs/index.cfm?id_articolo_numero=3109 |author-separator=, |author2=Pardini E |author3=Genovesi M |display-authors=3 |last4=Campomori |first4=A |last5=Grasso |first5=L |last6=Morselli |first6=LL |last7=Lupi |first7=I |last8=Pellegrini |first8=G |last9=Bartalena |first9=L}}</ref><ref name="pmid14637271">{{cite journal |author=Wiesli P, Schwegler B, Spinas GA, Schmid C |title=Serum cystatin C is sensitive to small changes in thyroid function |journal=Clin. Chim. Acta |volume=338 |issue=1–2 |pages=87–90 |year=2003 |month=December |pmid=14637271 |doi= 10.1016/j.cccn.2003.07.022|url=http://linkinghub.elsevier.com/retrieve/pii/S0009898103004145}}</ref> and glucocorticoid therapy in some<ref name="pmid11673383">{{cite journal |author=Risch L, Herklotz R, Blumberg A, Huber AR |title=Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients |journal=Clin. Chem. |volume=47 |issue=11 |pages=2055–9 |year=2001 |month=November |pmid=11673383 |doi= |url=http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=11673383}}</ref><ref name="pmid10958865">{{cite journal |author=Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J |title=Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients |journal=Clin. Chim. Acta |volume=300 |issue=1–2 |pages=83–95 |year=2000 |month=October |pmid=10958865 |doi= 10.1016/S0009-8981(00)00298-9|url=http://linkinghub.elsevier.com/retrieve/pii/S0009-8981(00)00298-9}}</ref> but not all<ref name="pmid12089191">{{cite journal |author=Bökenkamp A, van Wijk JA, Lentze MJ, Stoffel-Wagner B |title=Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations |journal=Clin. Chem. |volume=48 |issue=7 |pages=1123–6 |year=2002 |month=July |pmid=12089191 |doi= |url=http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=12089191}}</ref> situations. Other reports have found that levels are influenced by [[cigarette smoking]] and levels of [[C-reactive protein]].<ref name="pmid15086483">{{cite journal |author=Knight EL |title=Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement |journal=Kidney Int. |volume=65 |issue=4 |pages=1416–1421 |year=2004 |month=April |pmid=15086483 |doi=10.1111/j.1523-1755.2004.00517.x |author-separator=, |author2=Verhave JC |author3=Spiegelman D |display-authors=3 |last4=Hillege |first4=Hans L. |last5=De Zeeuw |first5=Dick |last6=Curhan |first6=Gary C. |last7=De Jong |first7=Paul E.}}</ref> Levels seem to be increased in [[HIV]] infection, which might or might not reflect actual renal dysfunction.<ref name="pmid17998494">{{cite journal |author=Odden MC |title=Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study |journal=Arch. Intern. Med. |volume=167 |issue=20 |pages=2213–2219 |year=2007 |month=November |pmid=17998494 |doi=10.1001/archinte.167.20.2213 |url=http://archinte.ama-assn.org/cgi/pmidlookup?view=long&pmid=17998494 |author-separator=, |author2=Scherzer R |author3=Bacchetti P |display-authors=3 |last4=Szczech |first4=L. A. |last5=Sidney |first5=S. |last6=Grunfeld |first6=C. |last7=Shlipak |first7=M. G.}}</ref><ref name="pmid1569212">{{cite journal |author=Collé A |title=Cystatin C levels in sera of patients with human immunodeficiency virus infection. A new avidin-biotin ELISA assay for its measurement |journal=J Immunoassay |volume=13 |issue=1 |pages=47–60 |year=1992 |pmid=1569212 |doi= 10.1080/15321819208019824|url= |author-separator=, |author2=Tavera C |author3=Prévot D |display-authors=3 |last4=Leung-Tack |first4=Jeanne |last5=Thomas |first5=Yolène |last6=Manuel |first6=Yves |last7=Benveniste |first7=Jacques |last8=Leibowitch |first8=Jacques}}</ref><ref name="pmid16964834">{{cite journal |author=Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW, Prokopowicz D, Rogalska M, Parfieniuk A |title=Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration |journal=Antivir. Ther. (Lond.) |volume=11 |issue=5 |pages=641–5 |year=2006 |pmid=16964834 |doi= |url=}}</ref> The role of cystatin C to monitor GFR during pregnancy remains controversial.<ref name="pmid12004930">{{cite journal |author=Strevens H, Wide-Swensson D, Torffvit O, Grubb A |title=Serum cystatin C for assessment of glomerular filtration rate in pregnant and non-pregnant women. Indications of altered filtration process in pregnancy |journal=Scand. J. Clin. Lab. Invest. |volume=62 |issue=2 |pages=141–147 |year=2002 |pmid=12004930 |doi= 10.1080/003655102753611771|url=}}</ref><ref name="pmid15842279">{{cite journal |author=Akbari A |title=Cystatin-C and beta trace protein as markers of renal function in pregnancy |journal=BJOG |volume=112 |issue=5 |pages=575–578 |year=2005 |month=May |pmid=15842279 |doi=10.1111/j.1471-0528.2004.00492.x |author-separator=, |author2=Lepage N |author3=Keely E |display-authors=3 |last4=Clark |first4=Heather D. |last5=Jaffey |first5=James |last6=MacKinnon |first6=Martin |last7=Filler |first7=Guido}}</ref> Like creatinine, the elimination of cystatin C via routes other than the kidney increase with worsening GFR.<ref name="pmid16025834">{{cite journal |author=Sjöström P, Tidman M, Jones I |title=Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans |journal=Scand. J. Clin. Lab. Invest. |volume=65 |issue=2 |pages=111–124 |year=2005 |pmid=16025834 |doi= 10.1080/00365510510013523|url=}}</ref>

===Death and cardiovascular disease===
Kidney dysfunction increases the risk of death and cardiovascular disease.<ref name="pmid16738019">{{cite journal |author=Tonelli M |title=Chronic kidney disease and mortality risk: a systematic review |journal=J. Am. Soc. Nephrol. |volume=17 |issue=7 |pages=2034–2047 |year=2006 |month=July |pmid=16738019 |doi=10.1681/ASN.2005101085 |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=16738019 |author-separator=, |author2=Wiebe N |author3=Culleton B |display-authors=3 |last4=House |first4=A |last5=Rabbat |first5=C |last6=Fok |first6=M |last7=McAlister |first7=F |last8=Garg |first8=AX}}</ref><ref name="pmid15385656">{{cite journal |author=Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY |title=Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization |journal=N. Engl. J. Med. |volume=351 |issue=13 |pages=1296–1305 |year=2004 |month=September |pmid=15385656 |doi=10.1056/NEJMoa041031 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15385656&promo=ONFLNS19}}</ref>
Several studies have found that increased levels of cystatin C are associated with the risk of death, several types of cardiovascular disease (including [[myocardial infarction]], [[stroke]], [[heart failure]], [[peripheral arterial disease]] and [[metabolic syndrome]]) and healthy aging. Some studies have found cystatin C to be better in this regard than serum creatinine or creatinine-based GFR equations.<ref name="pmid18480203">{{cite journal |author=Zethelius B |title=Use of multiple biomarkers to improve the prediction of death from cardiovascular causes |journal=N. Engl. J. Med. |volume=358 |issue=20 |pages=2107–2116 |year=2008 |month=May |pmid=18480203 |doi=10.1056/NEJMoa0707064 |url= |author-separator=, |author2=Berglund L |author3=Sundström J |display-authors=3 |last4=Ingelsson |first4=Erik |last5=Basu |first5=Samar |last6=Larsson |first6=Anders |last7=Venge |first7=Per |last8=Ärnlöv |first8=Johan}}</ref><ref name="pmid15901858">{{cite journal |author=Shlipak MG |title=Cystatin C and the risk of death and cardiovascular events among elderly persons |journal=N. Engl. J. Med. |volume=352 |issue=20 |pages=2049–2060 |year=2005 |month=May |pmid=15901858 |doi=10.1056/NEJMoa043161 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15901858&promo=ONFLNS19 |author-separator=, |author2=Sarnak MJ |author3=Katz R |display-authors=3 |last4=Fried |first4=Linda F. |last5=Seliger |first5=Stephen L. |last6=Newman |first6=Anne B. |last7=Siscovick |first7=David S. |last8=Stehman-Breen |first8=Catherine}}</ref><ref name="pmid17190862">{{cite journal |author=Ix JH, Shlipak MG, Chertow GM, Whooley MA |title=Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study |journal=Circulation |volume=115 |issue=2 |pages=173–179 |year=2007 |month=January |pmid=17190862 |doi=10.1161/CIRCULATIONAHA.106.644286 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=17190862 |pmc=2771187}}</ref><ref name="pmid18082491">{{cite journal |author=Deo R |title=Kidney dysfunction and fatal cardiovascular disease--an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study |journal=Am. Heart J. |volume=155 |issue=1 |pages=62–68 |year=2008 |month=January |pmid=18082491 |doi=10.1016/j.ahj.2007.08.012 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(07)00687-4 |author-separator=, |author2=Fyr CL |author3=Fried LF |display-authors=3 |last4=Newman |first4=A |last5=Harris |first5=T |last6=Angleman |first6=S |last7=Green |first7=C |last8=Kritchevsky |first8=S |last9=Chertow |first9=G}}</ref><ref name="pmid15563478">{{cite journal |author=Koenig W, Twardella D, Brenner H, Rothenbacher D |title=Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate |journal=Clin. Chem. |volume=51 |issue=2 |pages=321–327 |year=2005 |month=February |pmid=15563478 |doi=10.1373/clinchem.2004.041889 |url=http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=15563478}}</ref><ref name="pmid15477399">{{cite journal |author=Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L |title=Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome |journal=Circulation |volume=110 |issue=16 |pages=2342–2348 |year=2004 |month=October |pmid=15477399 |doi=10.1161/01.CIR.0000145166.44942.E0 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=15477399}}</ref><ref name="pmid16046222">{{cite journal |author=Luc G |title=Plasma cystatin-C and development of coronary heart disease: The PRIME Study |journal=Atherosclerosis |volume=185 |issue=2 |pages=375–380 |year=2006 |month=April |pmid=16046222 |doi=10.1016/j.atherosclerosis.2005.06.017 |url=http://linkinghub.elsevier.com/retrieve/pii/S0021-9150(05)00390-4 |author-separator=, |author2=Bard JM |author3=Lesueur C |display-authors=3 |last4=Arveiler |first4=D |last5=Evans |first5=A |last6=Amouyel |first6=P |last7=Ferrieres |first7=J |last8=Juhanvague |first8=I |last9=Fruchart |first9=J}}</ref><ref name="pmid18456039">{{cite journal |author=Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C |title=Is serum cystatin-C a reliable marker for metabolic syndrome? |journal=Am. J. Med. |volume=121 |issue=5 |pages=426–432 |year=2008 |month=May |pmid=18456039 |doi=10.1016/j.amjmed.2008.01.040 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(08)00150-2}}</ref><ref name="pmid17606957">{{cite journal |author=Menon V |title=Cystatin C as a risk factor for outcomes in chronic kidney disease |journal=Ann. Intern. Med. |volume=147 |issue=1 |pages=19–27 |year=2007 |month=July |pmid=17606957 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=reprint&pmid=17606957 |author-separator=, |author2=Shlipak MG |author3=Wang X |display-authors=3 |last4=Coresh |first4=J |last5=Greene |first5=T |last6=Stevens |first6=L |last7=Kusek |first7=JW |last8=Beck |first8=GJ |last9=Collins |first9=AJ}}</ref><ref name="pmid18227360">{{cite journal |author=Sarnak MJ |title=Cystatin C and aging success |journal=Arch. Intern. Med. |volume=168 |issue=2 |pages=147–153 |year=2008 |month=January |pmid=18227360 |doi=10.1001/archinternmed.2007.40 |url=http://archinte.ama-assn.org/cgi/pmidlookup?view=long&pmid=18227360 |pmc=2871318 |author-separator=, |author2=Katz R |author3=Fried LF |display-authors=3 |last4=Siscovick |first4=D. |last5=Kestenbaum |first5=B. |last6=Seliger |first6=S. |last7=Rifkin |first7=D. |last8=Tracy |first8=R. |last9=Newman |first9=A. B.}}</ref><ref name="pmid18082494">{{cite journal |author=Djoussé L, Kurth T, Gaziano JM |title=Cystatin C and risk of heart failure in the Physicians' Health Study (PHS) |journal=Am. Heart J. |volume=155 |issue=1 |pages=82–86 |year=2008 |month=January |pmid=18082494 |doi=10.1016/j.ahj.2007.08.023 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(07)00709-0 |pmc=2179893}}</ref><ref name="pmid16344426">{{cite journal |author=O'Hare AM |title=Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study |journal=Arch. Intern. Med. |volume=165 |issue=22 |pages=2666–2670 |year=2005 |pmid=16344426 |doi=10.1001/archinte.165.22.2666 |url=http://archinte.ama-assn.org/cgi/pmidlookup?view=long&pmid=16344426 |author-separator=, |author2=Newman AB |author3=Katz R |display-authors=3 |last4=Fried |first4=LF |last5=Stehman-Breen |first5=CO |last6=Seliger |first6=SL |last7=Siscovick |first7=DS |last8=Shlipak |first8=MG}}</ref>
Because the association of cystatin C with long term outcomes has appeared stronger than what could be expected for GFR, it has been hypothesized that cystatin C might also be linked to mortality in a way independent of kidney function.<ref name="pmid15901867">{{cite journal |author=Stevens LA, Levey AS |title=Chronic kidney disease in the elderly--how to assess risk |journal=N. Engl. J. Med. |volume=352 |issue=20 |pages=2122–2124 |year=2005 |month=May |pmid=15901867 |doi=10.1056/NEJMe058035 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15901867&promo=ONFLNS19}}</ref> In keeping with its [[housekeeping gene]] properties, it has been suggested that cystatin C might be influenced by the [[basal metabolic rate]].<ref name="pmid18283218">{{cite journal |author=Delanaye P, Cavalier E, Krzesinski JM |title=Cystatin C, renal function, and cardiovascular risk |journal=Ann. Intern. Med. |volume=148 |issue=4 |pages=323 |year=2008 |month=February |pmid=18283218 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=long&pmid=18283218}}</ref>

===Neurologic disorders===
[[Mutation]]s in the cystatin 3 [[gene]] are responsible for the [[Iceland]]ic type of hereditary [[cerebral amyloid angiopathy]], a condition predisposing to [[intracerebral haemorrhage]], [[stroke]] and [[dementia]].<ref name="pmid2541223">{{cite journal |author=Levy E, Lopez-Otin C, Ghiso J, Geltner D, Frangione B |title=Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases |journal=J. Exp. Med. |volume=169 |issue=5 |pages=1771–1778 |year=1989 |month=May |pmid=2541223 |doi= 10.1084/jem.169.5.1771|url= |pmc=2189307 }}</ref><ref name="pmid16612983">{{cite journal |author=Levy E, Jaskolski M, Grubb A |title=The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models |journal=Brain Pathol. |volume=16 |issue=1 |pages=60–70 |year=2006 |month=January |pmid=16612983 |doi= 10.1111/j.1750-3639.2006.tb00562.x|url=}}</ref> The condition is inherited in a [[Dominance relationship|dominant fashion]].

Since cystatin 3 also binds [[amyloid β]] and reduces its aggregation and deposition, it is a potential target in [[Alzheimer's disease]].<ref name="pmid18026100">{{cite journal |author=Mi W |title=Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models |journal=Nat. Genet. |volume=39 |issue=12 |pages=1440–1442 |year=2007 |month=December |pmid=18026100 |doi=10.1038/ng.2007.29 |author-separator=, |author2=Pawlik M |author3=Sastre M |display-authors=3 |last4=Jung |first4=Sonia S |last5=Radvinsky |first5=David S |last6=Klein |first6=Andrew M |last7=Sommer |first7=John |last8=Schmidt |first8=Stephen D |last9=Nixon |first9=Ralph A}}</ref><ref name="pmid18026102">{{cite journal |author=Kaeser SA |title=Cystatin C modulates cerebral beta-amyloidosis |journal=Nat. Genet. |volume=39 |issue=12 |pages=1437–1439 |year=2007 |month=December |pmid=18026102 |doi=10.1038/ng.2007.23 |author-separator=, |author2=Herzig MC |author3=Coomaraswamy J |display-authors=3 |last4=Kilger |first4=Ellen |last5=Selenica |first5=Maj-Linda |last6=Winkler |first6=David T |last7=Staufenbiel |first7=Matthias |last8=Levy |first8=Efrat |last9=Grubb |first9=Anders}}</ref> Although not all studies have confirmed this, the overall evidence is in favor of are role for CST3 as a susceptibility gene for Alzheimer's disease.<ref name="pmid17192785">{{cite journal |author=Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE |title=Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database |journal=Nat. Genet. |volume=39 |issue=1 |pages=17–23 |year=2007 |month=January |pmid=17192785 |doi=10.1038/ng1934}}</ref> Cystatin C levels have been reported to be higher in subjects with Alzheimer's disease.<ref name="pmid17310123">{{cite journal |author=Chuo LJ, Sheu WH, Pai MC, Kuo YM |title=Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease |journal=Dement Geriatr Cogn Disord |volume=23 |issue=4 |pages=251–257 |year=2007 |pmid=17310123 |doi=10.1159/000100021 |url=http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000100021}}</ref>

The role of cystatin C in [[multiple sclerosis]] and other [[demyelinating disease]]s (characterized by a loss of the myelin nerve sheath) remains controversial.<ref name="pmid17006926">{{cite journal |author=Del Boccio P |title=Cleavage of cystatin C is not associated with multiple sclerosis |journal=Ann. Neurol. |volume=62 |issue=2 |pages=201–204 |year=2007 |month=August |pmid=17006926 |doi=10.1002/ana.20968 |author-separator=, |author2=Pieragostino D |author3=Lugaresi A |display-authors=3 |last4=Di Ioia |first4=Maria |last5=Pavone |first5=Barbara |last6=Travaglini |first6=Daniela |last7=d'Aguanno |first7=Simona |last8=Bernardini |first8=Sergio |last9=Sacchetta |first9=Paolo}}</ref>

===Other roles===
Cystatin C levels are decreased in [[atherosclerosis|atherosclerotic]] (so-called 'hardening' of the arteries) and [[aneurysm]]al (saccular bulging) lesions of the [[aorta]].<ref name="pmid10545518">{{cite journal |author=Shi GP |title=Cystatin C deficiency in human atherosclerosis and aortic aneurysms |journal=J. Clin. Invest. |volume=104 |issue=9 |pages=1191–1197 |year=1999 |month=November |pmid=10545518 |doi=10.1172/JCI7709 |pmc=409823 |author-separator=, |author2=Sukhova GK |author3=Grubb A |display-authors=3 |last4=Ducharme |first4=Anique |last5=Rhode |first5=Luis H. |last6=Lee |first6=Richard T. |last7=Ridker |first7=Paul M. |last8=Libby |first8=Peter |last9=Chapman |first9=Harold A.}}</ref><ref name="pmid18155003">{{cite journal |author=Abisi S, Burnand KG, Waltham M, Humphries J, Taylor PR, Smith A |title=Cysteine protease activity in the wall of abdominal aortic aneurysms |journal=J. Vasc. Surg. |volume=46 |issue=6 |pages=1260–1266 |year=2007 |month=December |pmid=18155003 |doi=10.1016/j.jvs.2007.08.015 |url=http://linkinghub.elsevier.com/retrieve/pii/S0741-5214(07)01343-2}}</ref><ref name="pmid17322367">{{cite journal |author=Abdul-Hussien H |title=Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases |journal=Am. J. Pathol. |volume=170 |issue=3 |pages=809–817 |year=2007 |month=March |pmid=17322367 |doi=10.2353/ajpath.2007.060522 |url=http://ajp.amjpathol.org/cgi/pmidlookup?view=long&pmid=17322367 |format= &ndash; <sup>[http://scholar.google.co.uk/scholar?hl=en&lr=&q=intitle%3ACollagen+degradation+in+the+abdominal+aneurysm%3A+a+conspiracy+of+matrix+metalloproteinase+and+cysteine+collagenases&as_publication=Am.+J.+Pathol.&as_ylo=2007&as_yhi=2007&btnG=Search Scholar search]</sup> |pmc=1864891 |author-separator=, |author2=Soekhoe RG |author3=Weber E |display-authors=3 |last4=Von Der Thüsen |first4=Jan H. |last5=Kleemann |first5=Robert |last6=Mulder |first6=Adri |last7=Van Bockel |first7=J. Hajo |last8=Hanemaaijer |first8=Roeland |last9=Lindeman |first9=Jan H.N.}} {{dead link|date=April 2009}}</ref><ref name="pmid10481531">{{cite journal |author=Gacko M, Chyczewski L, Chrostek L |title=Distribution, activity and concentration of cathepsin B and cystatin C in the wall of aortic aneurysm |journal=Pol J Pathol |volume=50 |issue=2 |pages=83–6 |year=1999 |pmid=10481531 |doi= |url=}}</ref>
Genetic and prognostic studies also suggest a role for cystatin C.<ref name="pmid14716800">{{cite journal |author=Eriksson P, Jones KG, Brown LC, Greenhalgh RM, Hamsten A, Powell JT |title=Genetic approach to the role of cysteine proteases in the expansion of abdominal aortic aneurysms |journal=Br J Surg |volume=91 |issue=1 |pages=86–89 |year=2004 |month=January |pmid=14716800 |doi=10.1002/bjs.4364}}</ref><ref name="pmid11683743">{{cite journal |author=Lindholt JS, Erlandsen EJ, Henneberg EW |title=Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms |journal=Br J Surg |volume=88 |issue=11 |pages=1472–1475 |year=2001 |month=November |pmid=11683743 |doi=10.1046/j.0007-1323.2001.01911.x}}</ref>
Breakdown of parts of the vessel wall in these conditions is thought to result from an imbalance between proteinases ([[cysteine protease]]s and [[matrix metalloproteinase]]s, increased) and their inhibitors (such as cystatin C, decreased).

A few studies have looked at the role of cystatin C or the CST3 gene in [[age-related macular degeneration]].<ref name="pmid11815350">{{cite journal |author=Zurdel J, Finckh U, Menzer G, Nitsch RM, Richard G |title=CST3 genotype associated with exudative age related macular degeneration |journal=Br J Ophthalmol |volume=86 |issue=2 |pages=214–219 |year=2002 |month=February |pmid=11815350 |doi= 10.1136/bjo.86.2.214|url=http://bjo.bmj.com/cgi/pmidlookup?view=long&pmid=11815350 |pmc=1771004}}</ref><ref name="pmid16893541">{{cite journal |author=Im E, Kazlauskas A |title=The role of cathepsins in ocular physiology and pathology |journal=Exp. Eye Res. |volume=84 |issue=3 |pages=383–388 |year=2007 |month=March |pmid=16893541 |doi=10.1016/j.exer.2006.05.017 |url=http://linkinghub.elsevier.com/retrieve/pii/S0014-4835(06)00271-5}}</ref> Cystatin C has also been investigated as a prognostic marker in several forms of cancer.<ref name="pmid15138478">{{cite journal |author=Strojan P, Oblak I, Svetic B, Smid L, Kos J |title=Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis |journal=Br. J. Cancer |volume=90 |issue=10 |pages=1961–1968 |year=2004 |month=May |pmid=15138478 |doi=10.1038/sj.bjc.6601830 |pmc=2409457}}</ref><ref name="pmid10690531">{{cite journal |author=Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brünner N |title=Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis |journal=Clin. Cancer Res. |volume=6 |issue=2 |pages=505–11 |year=2000 |month=February |pmid=10690531 |doi= |url=http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=10690531}}</ref> Its role in [[pre-eclampsia]] remains to be confirmed.<ref name="pmid14511964">{{cite journal |author=Strevens H |title=Serum cystatin C reflects glomerular endotheliosis in normal, hypertensive and pre-eclamptic pregnancies |journal=BJOG |volume=110 |issue=9 |pages=825–830 |year=2003 |month=September |pmid=14511964 |doi= 10.1111/j.1471-0528.2003.02051.x|url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=1470-0328&date=2003&volume=110&issue=9&spage=825 |author-separator=, |author2=Wide-Swensson D |author3=Grubb A |display-authors=3 |last4=Hansen |first4=Alastair |last5=Horn |first5=Thomas |last6=Ingemarsson |first6=Ingemar |last7=Larsen |first7=Svend |last8=Nyengaard |first8=Jens R. |last9=Torffvit |first9=Ole}}</ref><ref name="pmid18197549">{{cite journal |author=Franceschini N, Qiu C, Barrow DA, Williams MA |title=Cystatin C and preeclampsia: a case control study |journal=Ren Fail |volume=30 |issue=1 |pages=89–95 |year=2008 |pmid=18197549 |doi=10.1080/08860220701742229 |url=http://www.informaworld.com/openurl?genre=article&doi=10.1080/08860220701742229&magic=pubmed |unused_data=1B69BA326FFE69C3F0A8F227DF8201D0}}</ref><ref name="pmid17653875">{{cite journal |author=Kristensen K |title=Cystatin C, beta-2-microglobulin and beta-trace protein in pre-eclampsia |journal=Acta Obstet Gynecol Scand |volume=86 |issue=8 |pages=921–926 |year=2007 |pmid=17653875 |doi=10.1080/00016340701318133 |url=http://www.informaworld.com/openurl?genre=article&doi=10.1080/00016340701318133&magic=pubmed |author-separator=, |author2=Wide-Swensson D |author3=Schmidt C |display-authors=3 |last4=Blirup-Jensen |first4=S. |last5=Lindström |first5=V. |last6=Strevens |first6=H. |last7=Grubb |first7=A. |unused_data=1B69BA326FFE69C3F0A8F227DF8201D0}}</ref><ref name="pmid17227816">{{cite journal |author=Kristensen K, Larsson I, Hansson SR |title=Increased cystatin C expression in the pre-eclamptic placenta |journal=Mol. Hum. Reprod. |volume=13 |issue=3 |pages=189–195* |year=2007 |month=March |pmid=17227816 |doi=10.1093/molehr/gal111 |url=http://molehr.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17227816}}</ref>

==Laboratory measurement==
Cystatin C can be measured in a random sample of serum (the fluid in [[blood]] from which the [[red blood cell]]s and [[clotting factors]] have been removed) using [[immunoassay]]s such as [[nephelometry]] or particle-enhanced [[turbidimetry]].<ref name="pmid17624320"/> It is a more expensive test than serum creatinine (around $2 or $3, compared to $0.02 to $0.15), which can be measured with a Jaffé reaction.<ref name="pmid14687406">{{cite journal |author=Lamb EJ, O'Riordan SE, Webb MC, Newman DJ |title=Serum cystatin C may be a better marker of renal impairment than creatinine |journal=J Am Geriatr Soc |volume=51 |issue=11 |pages=1674–1675 |year=2003 |month=November |pmid=14687406 |doi= 10.1046/j.1532-5415.2003.515244.x|url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=0002-8614&date=2003&volume=51&issue=11&spage=1674}}</ref><ref name="pmid17581641">{{cite journal |author=Peake M, Whiting M |title=Measurement of serum creatinine - current status and future goals |journal=Clin Biochem Rev |volume=27 |issue=4 |pages=173–84 |year=2006 |month=November |pmid=17581641 |doi= |url= |pmc=1784008}}</ref><ref name="pmid16332993">{{cite journal |author=Myers GL |title=Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program |journal=Clin. Chem. |volume=52 |issue=1 |pages=5–18 |year=2006 |month=January |pmid=16332993 |doi=10.1373/clinchem.2005.0525144 |url=http://www.clinchem.org/cgi/pmidlookup?view=long&pmid=16332993 |author-separator=, |author2=Miller WG |author3=Coresh J |display-authors=3 |last4=Fleming |first4=J |last5=Greenberg |first5=N |last6=Greene |first6=T |last7=Hostetter |first7=T |last8=Levey |first8=AS |last9=Panteghini |first9=M}}</ref>

Reference values differ in many populations and with sex and age. Across different studies, the mean reference interval (as defined by the 5th and 95th [[percentile]]) was between 0.52 and 0.98&nbsp;mg/L. For women, the average reference interval is 0.52 to 0.90&nbsp;mg/L with a mean of 0.71&nbsp;mg/L. For men, the average reference interval is 0.56 to 0.98&nbsp;mg/L with a mean of 0.77&nbsp;mg/L.<ref name="pmid17624320">{{cite journal |author=Croda-Todd MT, Soto-Montano XJ, Hernández-Cancino PA, Juárez-Aguilar E |title=Adult cystatin C reference intervals determined by nephelometric immunoassay |journal=Clin. Biochem. |volume=40 |issue=13–14 |pages=1084–1087 |year=2007 |month=September |pmid=17624320 |doi=10.1016/j.clinbiochem.2007.05.011 |url=http://linkinghub.elsevier.com/retrieve/pii/S0009-9120(07)00215-9}}</ref>
The normal values decrease until the first year of life, remaining relatively stable before they increase again, especially beyond age 50.<ref name="NHNES"/><ref name="ADC">{{cite journal |author=Finney H, Newman DJ, Thakkar H, Fell JM, Price CP |title=Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children |journal=Arch. Dis. Child. |volume=82 |issue=1 |pages=71–75 |year=2000 |month=January |pmid=10630919 |doi= 10.1136/adc.82.1.71|url=http://adc.bmj.com/cgi/pmidlookup?view=long&pmid=10630919 |pmc=1718178}}</ref><ref name="pmid16730690">{{cite journal |author=Ognibene A |title=Cystatin C reference values and aging |journal=Clin. Biochem. |volume=39 |issue=6 |pages=658–661 |year=2006 |month=June |pmid=16730690 |doi=10.1016/j.clinbiochem.2006.03.017 |url=http://linkinghub.elsevier.com/retrieve/pii/S0009-9120(06)00139-1 |author-separator=, |author2=Mannucci E |author3=Caldini A |display-authors=3 |last4=Terreni |first4=A |last5=Brogi |first5=M |last6=Bardini |first6=G |last7=Sposato |first7=I |last8=Mosconi |first8=V |last9=Salvadori |first9=B}}</ref> Creatinine levels increase until puberty and differ according to gender from then on, making their interpretation problematic for pediatric patients.<ref name="ADC"/><ref name="Expertmeeting">{{cite journal |author=Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A |title=Cystatin C as a marker of GFR--history, indications, and future research |journal=Clin. Biochem. |volume=38 |issue=1 |pages=1–8 |year=2005 |month=January |pmid=15607309 |doi=10.1016/j.clinbiochem.2004.09.025 |url=http://linkinghub.elsevier.com/retrieve/pii/S0009-9120(04)00283-8}}</ref>

In a large study from the United States [[National Health and Nutrition Examination Survey]], the reference interval (as defined by the 1st and 99th [[percentile]]) was between 0.57 and 1.12&nbsp;mg/L. This interval was 0.55 - 1.18 for women and 0.60 - 1.11 for men. Non-Hispanic blacks and Mexican Americans had lower normal cystatin C levels.<ref name="NHNES">{{cite journal |author=Köttgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J |title=Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III) |journal=Am. J. Kidney Dis. |volume=51 |issue=3 |pages=385–394 |year=2008 |month=March |pmid=18295054 |doi=10.1053/j.ajkd.2007.11.019 |url=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(07)01595-8}}</ref> Other studies have found that in patients with an impaired renal function, women have lower and blacks have higher cystatin C levels for the same GFR.<ref name="Stevens2008"/> For example, the cut-off values of cystatin C for [[chronic kidney disease]] for a 60-year-old white women would be 1.12&nbsp;mg/L and 1.27&nbsp;mg/L in a black man (a 13% increase). For serum creatinine values adjusted with the MDRD equation, these values would be 0.95&nbsp;mg/dL to 1.46&nbsp;mg/dL (a 54% increase).<ref name="pmid18295049">{{cite journal |author=Shlipak MG |title=Cystatin C: research priorities targeted to clinical decision making |journal=Am. J. Kidney Dis. |volume=51 |issue=3 |pages=358–361 |year=2008 |month=March |pmid=18295049 |doi=10.1053/j.ajkd.2008.01.002 |url=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(08)00039-5}}</ref>

Based on a threshold level of 1.09&nbsp;mg/L (the 99th percentile in a population of 20 to 39-year-olds without hypertension, diabetes, [[microalbuminuria]] or [[albuminuria|macroalbuminuria]] or higher than stage 3 chronic kidney disease), the [[prevalence]] of increased levels of cystatin C in the United States was 9.6% in subjects of normal weight, increasing in [[overweight]] and [[obese]] individuals.<ref name="pmid18374694">{{cite journal |author=Muntner P, Winston J, Uribarri J, Mann D, Fox CS |title=Overweight, obesity, and elevated serum cystatin C levels in adults in the United States |journal=Am. J. Med. |volume=121 |issue=4 |pages=341–348 |year=2008 |month=April |pmid=18374694 |doi=10.1016/j.amjmed.2008.01.003 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(08)00042-9 |pmc=3049932}}</ref> In Americans aged 60 and 80 and older, serum cystatin is increased in 41% and more than 50%.<ref name="NHNES"/>

==Molecular biology==
The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active [[Cysteine protease|cysteine protease inhibitor]]s, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins ([[stefin]]s), type 2 cystatins and the [[kininogen]]s. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. The cystatin [[gene locus|locus]] on the short arm of [[chromosome 20]] contains the majority of the type 2 cystatin genes and [[pseudogene]]s.

The CST3 gene is located in the cystatin locus and comprises 3 [[exon]]s (coding regions, as opposed to [[intron]]s, non-coding regions within a gene), spanning 4.3 [[kilo-base pair]]s. It encodes the most abundant extracellular inhibitor of cysteine proteases. It is found in high concentrations in biological fluids and is expressed in virtually all organs of the body (CST3 is a [[housekeeping gene]]). The highest levels are found in [[semen]], followed by [[breastmilk]], [[tears]] and [[saliva]]. The [[hydrophobic]] [[Leader sequence (mRNA)|leader sequence]] indicates that the protein is normally secreted. There are three [[Polymorphism (biology)|polymorphisms]] in the [[promoter (biology)|promoter]] region of the gene, resulting in two common variants.<ref>{{cite web | title = Entrez Gene: CST3 cystatin C (amyloid angiopathy and cerebral hemorrhage)| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1471| accessdate = }}</ref> Several [[single nucleotide polymorphism]]s have been associated with altered cystatin C levels.<ref name="pmid17903292">{{cite journal |author=Hwang SJ, Yang Q, Meigs JB, Pearce EN, Fox CS |title=A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study |journal=BMC Med. Genet. |volume=8 Suppl 1|pages=S10 |year=2007 |pmid=17903292 |doi=10.1186/1471-2350-8-S1-S10 |url=http://www.biomedcentral.com/1471-2350/8%20Suppl%201/S10 |pmc=1995611}}</ref>

Cystatin C is a non-[[Glycosylation|glycosylated]], [[Base (chemistry)|basic]] protein ([[isoelectric point]] at [[pH]] 9.3). The [[Protein structure|crystal structure]] of cystatin C is characterized by a short [[alpha helix]] and a long alpha helix which lies across a large antiparallel, five-[[beta strand|stranded]] [[beta sheet]]. Like other type 2 cystatins, it has two [[disulfide bond]]s. Around 50% of the molecules carry a [[Hydroxyproline|hydroxylated proline]]. Cystatin C forms [[protein dimer|dimer]]s (molecule pairs) by exchanging subdomains; in the paired state, each half is made up of the long alpha helix and one beta strand of one partner, and four beta strands of the other partner.<ref name="pmid11276250">{{cite journal |author=Janowski R |title=Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping |journal=Nat. Struct. Biol. |volume=8 |issue=4 |pages=316–320 |year=2001 |month=April |pmid=11276250 |doi=10.1038/86188 |author-separator=, |author2=Kozak M |author3=Jankowska E |display-authors=3 |last4=Grzonka |first4=Zbigniew |last5=Grubb |first5=Anders |last6=Abrahamson |first6=Magnus |last7=Jaskolski |first7=Mariusz}}</ref>

==History==
Cystatin C was first described as 'gamma-trace' in 1961 as a trace protein together with other ones (such as beta-trace) in the [[cerebrospinal fluid]] and in the [[urine]] of patients with [[renal failure]].<ref name="pmid6283552">{{cite journal |author=Grubb A, Löfberg H |title=Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=79 |issue=9 |pages=3024–3027 |year=1982 |month=May |pmid=6283552 |doi= 10.1073/pnas.79.9.3024|url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=6283552 |pmc=346341}}</ref> Grubb and Löfberg first reported its amino acid sequence.<ref name="pmid6283552"/> They noticed it was increased in patients with advanced [[renal failure]].<ref name="pmid119302">{{cite journal |author=Löfberg H, Grubb AO |title=Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system |journal=Scand. J. Clin. Lab. Invest. |volume=39 |issue=7 |pages=619–626 |year=1979 |month=November |pmid=119302 |doi= 10.3109/00365517909108866|url=}}</ref> It was first proposed as a measure of glomerular filtration rate by Grubb and coworkers in 1985.<ref name="pmid3911736">{{cite journal |author=Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H |title=Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate |journal=Acta Med Scand |volume=218 |issue=5 |pages=499–503 |year=1985 |pmid=3911736 |doi= 10.1111/j.0954-6820.1985.tb08880.x|url=}}</ref><ref name="pmid3923607">{{cite journal |author=Simonsen O, Grubb A, Thysell H |title=The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate |journal=Scand. J. Clin. Lab. Invest. |volume=45 |issue=2 |pages=97–101 |year=1985 |month=April |pmid=3923607 |doi= 10.3109/00365518509160980|url=}}</ref>

Use of serum creatinine and cystatin C was found very effective in accuratetly reflecting the GFR in a study reported in the July 5, 2012 issue of the New England Journal of Medicine. 

==Footnotes==
{{reflist|2}}

==External links==
* The [[MEROPS]] online database for peptidases and their inhibitors: [http://merops.sanger.ac.uk/cgi-bin/merops.cgi?id=I25.004 I25.004]

<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{PBB_Controls
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = no
| update_citations = no}}
{{Amyloidosis}}
[[Category:Proteins]]
[[Category:Nephrology]]